PMID- 21924673
OWN - NLM
STAT- MEDLINE
DCOM- 20120301
LR  - 20131121
IS  - 1873-5967 (Electronic)
IS  - 1386-6532 (Linking)
VI  - 52
IP  - 4
DP  - 2011 Dec
TI  - Successful treatment of acute hepatitis C virus in HIV positive patients using 
      the European AIDS Treatment Network guidelines for treatment duration.
PG  - 367-9
LID - 10.1016/j.jcv.2011.08.020 [doi]
AB  - BACKGROUND: The incidence of acute hepatitis C virus (HCV) in HIV-positive 
      patients is rising. Recent studies summarized by the European AIDS Treatment 
      Network (NEAT)(1) show that pegylated interferon alpha (PEG-IFNalpha) and ribavirin 
      can lead to a sustained virological response (SVR) in approximately 60-80% of 
      patients. Controversy remains on when to start treatment and whether 24 or 48 
      weeks of treatment lead to better outcomes. OBJECTIVES: To assess the 
      effectiveness of a treatment strategy for acute HCV infection in HIV-positive 
      patients, in which patients with undetectable HCV RNA at 4 weeks (rapid 
      virological response, RVR) receive 24 weeks, while those without receive 48 weeks 
      of PEG-IFNalpha and ribavirin, as per the NEAT guidelines. STUDY DESIGN: A 
      retrospective cohort study of HIV-positive patients diagnosed with acute HCV 
      infection between December 2006 and May 2010. Those who received acute treatment 
      with PEG-IFNalpha and ribavirin had HCV RNA levels monitored and outcomes evaluated. 
      For patients who did not receive acute treatment, the reason for deferral and 
      most recent available HCV RNA were recorded. RESULTS: Twenty-two patients 
      received acute treatment with PEG-IFNalpha and ribavirin. Twelve patients achieved 
      RVR and had 24 weeks treatment, 10 patients had no RVR and had 48 weeks 
      treatment. Two patients discontinued treatment (due to adverse effects [AEs] and 
      failure to suppress HCV RNA sufficiently at 12 weeks). All 20 patients who 
      completed treatment had SVR. CONCLUSION: Our high SVR rate of 91% supports the 
      new NEAT treatment duration recommendations.
CI  - Copyright (c) 2011 Elsevier B.V. All rights reserved.
FAU - Dorward, Jienchi
AU  - Dorward J
AD  - The Grahame Hayton Unit, Barts and the London NHS Trust, Royal London Hospital, 
      Whitechapel, London E1 1BB, United Kingdom.
FAU - Garrett, Nigel
AU  - Garrett N
FAU - Scott, Duncan
AU  - Scott D
FAU - Buckland, Matthew
AU  - Buckland M
FAU - Orkin, Chloe
AU  - Orkin C
FAU - Baily, Guy
AU  - Baily G
LA  - eng
PT  - Journal Article
DEP - 20110915
PL  - Netherlands
TA  - J Clin Virol
JT  - Journal of clinical virology : the official publication of the Pan American 
      Society for Clinical Virology
JID - 9815671
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon-alpha)
RN  - 0 (RNA, Viral)
RN  - 49717AWG6K (Ribavirin)
SB  - IM
MH  - Adult
MH  - Antiviral Agents/*administration & dosage
MH  - Cohort Studies
MH  - Female
MH  - HIV Infections/*complications
MH  - Hepatitis C/*drug therapy
MH  - Humans
MH  - Interferon-alpha/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Practice Guidelines as Topic
MH  - RNA, Viral/blood
MH  - Retrospective Studies
MH  - Ribavirin/*administration & dosage
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2011/09/20 06:00
MHDA- 2012/03/02 06:00
CRDT- 2011/09/20 06:00
PHST- 2011/06/30 00:00 [received]
PHST- 2011/08/21 00:00 [revised]
PHST- 2011/08/22 00:00 [accepted]
PHST- 2011/09/20 06:00 [entrez]
PHST- 2011/09/20 06:00 [pubmed]
PHST- 2012/03/02 06:00 [medline]
AID - S1386-6532(11)00357-X [pii]
AID - 10.1016/j.jcv.2011.08.020 [doi]
PST - ppublish
SO  - J Clin Virol. 2011 Dec;52(4):367-9. doi: 10.1016/j.jcv.2011.08.020. Epub 2011 Sep 
      15.